Trial · NCT05850520
Results by group47
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 47
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 36 | Aflibercept 2q4 | 17.5 | Standard Error 0.7 | Letters | |
| Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 36 | Aflibercept 8q8/3 | 17.4 | Standard Error 0.7 | Letters | |
| Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 36 | Aflibercept 8q8/5 | 18.3 | Standard Error 0.6 | Letters | |
| Number of Active Injections From Baseline to Week 36 | Aflibercept 2q4 | 8.8 | Standard Error 0.0 | Number of active injections | |
| Number of Active Injections From Baseline to Week 36 | Aflibercept 8q8/3 | 6.1 | Standard Error 0.0 | Number of active injections | |
| Number of Active Injections From Baseline to Week 36 | Aflibercept 8q8/5 | 6.9 | Standard Error 0.0 | Number of active injections | |
| Participants Gaining at Least 15 Letters in BCVA From Baseline at Week 36 | Aflibercept 2q4 | 158 | Participants | ||
| Participants Gaining at Least 15 Letters in BCVA From Baseline at Week 36 | Aflibercept 8q8/3 | 153 | Participants | ||
| Participants Gaining at Least 15 Letters in BCVA From Baseline at Week 36 | Aflibercept 8q8/5 | 161 | Participants | ||
| Participants Achieving an ETDRS Letter Score of at Least 69 (Approximate 20/40 Snellen Equivalent) at Week 36 | Aflibercept 2q4 | 179 | Participants | ||
| Participants Achieving an ETDRS Letter Score of at Least 69 (Approximate 20/40 Snellen Equivalent) at Week 36 | Aflibercept 8q8/3 | 189 | Participants | ||
| Participants Achieving an ETDRS Letter Score of at Least 69 (Approximate 20/40 Snellen Equivalent) at Week 36 | Aflibercept 8q8/5 | 189 | Participants | ||
| Participants Having no Intraretinal Fluid (IRF) and no Sub-retinal Fluid (SRF) in the Center Subfield at Week 36 | Aflibercept 2q4 | 221 | Participants | ||
| Participants Having no Intraretinal Fluid (IRF) and no Sub-retinal Fluid (SRF) in the Center Subfield at Week 36 | Aflibercept 8q8/3 | 211 | Participants | ||
| Participants Having no Intraretinal Fluid (IRF) and no Sub-retinal Fluid (SRF) in the Center Subfield at Week 36 | Aflibercept 8q8/5 | 202 | Participants | ||
| Change From Baseline in Central Sub-field Thickness (CST) at Week 36 | Aflibercept 2q4 | -370.8 | Standard Error 3.9 | μm | |
| Change From Baseline in Central Sub-field Thickness (CST) at Week 36 | Aflibercept 8q8/3 | -370.9 | Standard Error 3.1 | μm | |
| Change From Baseline in Central Sub-field Thickness (CST) at Week 36 | Aflibercept 8q8/5 | -369.5 | Standard Error 2.3 | μm | |
| Change From Baseline in NEI VFQ 25 Total Score at Week 36 | Aflibercept 2q4 | 6.27 | Standard Error 0.67 | Scores on a scale | |
| Change From Baseline in NEI VFQ 25 Total Score at Week 36 | Aflibercept 8q8/3 | 5.91 | Standard Error 0.61 | Scores on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05850520/results